<DOC>
	<DOCNO>NCT00397657</DOCNO>
	<brief_summary>Recent evidence use statin therapy indicate potential ultra-low level low-density lipoprotein ( LDL-C ) provide great protection recurrent coronary heart disease ( CHD ) event . Thus , August 2005 , guideline treatment lipid disorder ( NCEP ATPIII ) revise indicate LDL-C treatment goal 70 mg/dL ( revise 100 mg/dL ) optional patient know CHD . In guideline , low level high-density lipoprotein ( HDL-C ) also suggest specifically proscribed target therapy . Recently ARBITER 2 trial provide first evidence potential raise HDL-C extended release niacin add statin monotherapy . However , whether approach would superior strategy low concentration LDL-C target unknown . The purpose ARBITER 6 - HALTS compare HDL LDL-focused strategy lipid treatment effect atherosclerosis . This study prospective , randomize , open-label , blind endpoint trial compare treatment strategy either HDL-raising therapy LDL reduction dyslipidemia carotid atherosclerosis . Subjects know atherosclerotic coronary vascular disease otherwise high cardiovascular risk presence coronary risk equivalent currently treat statin eligible . Subjects randomly assign allocation-concealed fashion open label treatment either Ezetimibe 10 mg/d additional LDL-lowering OR Extended-release niacin ( 1 gm/d , titrate max tolerable dose 2 gm/d ) HDL improvement . The effect 2 different strategy intensify lipid management atherosclerosis assess change carotid intima-media thickness , validated surrogate endpoint . The data help guide clinicians potential benefit lipid treatment strategy .</brief_summary>
	<brief_title>Comparative Study Effect Ezetimibe Versus Extended-Release Niacin Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male female subject , â‰¥ 30 year old either know atherosclerotic coronary vascular disease OR coronary risk equivalent define either : diabetes mellitus , multiple coronary risk factor Framingham Risk Score &gt; 2 % per year , elevate coronary calcium score ( &gt; 400 men , &gt; 200 woman ) Currently treat statin ( Simvastatin 20 mg/d equivalent ) monotherapy treatment hyperlipidemia Recent lipid ( within past 3 month without interval change statin regimen ) showing : LDLC &lt; 100 mg/dL HDLC &lt; 50 mg/dL ( men ) &lt; 55 mg/dL ( woman ) Current use know intolerance niacin ezetimibe Known history liver disease ( cirrhosis , chronic hepatitis ) abnormal liver associate enzyme , &gt; 3x upper laboratory reference value Enrollment another drug device research protocol Females pregnant , expect get pregnant course study , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>carotid intima medium thickness</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>niacin</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>HDL-C</keyword>
	<keyword>LDL-C</keyword>
</DOC>